Kazia Therapeutics Limited

Kazia Therapeutics Limited

$0.9
-0.34 (-27.76%)
NASDAQ
USD, AU
Biotechnology

52 Week Range

0.19-1.58

Beta

2.13

Market Cap

$11.91M

Last Dividend

0

PE (TTM)

-2.02

Dividend Yield (TTM)

0

Price Chart

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. John Edwin Friend II, M.D.

Full-Time Employees

9

IPO Date

1999-01-06

Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Phone

1300 787 272

Address

Three International Towers, Sydney, NSW, 2000, AU

CIK

0001075880